The presynaptic function as target for antidepressants (Englisch)
- Neue Suche nach: Popoli, M.
- Neue Suche nach: Consogno, E.
- Neue Suche nach: Nocera, A.
- Neue Suche nach: Racagni, G.
- Neue Suche nach: Popoli, M.
- Neue Suche nach: Consogno, E.
- Neue Suche nach: Nocera, A.
- Neue Suche nach: Racagni, G.
In:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
;
10
;
160
;
2000
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:The presynaptic function as target for antidepressants
-
Beteiligte:Popoli, M. ( Autor:in ) / Consogno, E. ( Autor:in ) / Nocera, A. ( Autor:in ) / Racagni, G. ( Autor:in )
-
Erschienen in:EUROPEAN NEUROPSYCHOPHARMACOLOGY ; 10 ; 160
-
Verlag:
- Neue Suche nach: ELSEVIER SCIENCE BV
-
Erscheinungsdatum:01.01.2000
-
Format / Umfang:160 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.8 / 615.1
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
-
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 10
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatmentAltamura, A.C. / Boin, F. / Maes, M. et al. | 1999
- 5
-
Chronic mild unpredictable stress after noradrenergic denervation: attenuation of behavioural and biochemical effects of DSP-4 treatmentHarro, J. / Haidkind, R. / Harro, M. / Modiri, A.-R. / Gillberg, P.-G. / Pahkla, R. / Matto, V. / Oreland, L. et al. | 1999
- 17
-
Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patientsScharfetter, J. / Chaudhry, H.R. / Hornik, K. / Fuchs, K. / Sieghart, W. / Kasper, S. / Aschauer, H.N. et al. | 1999
- 21
-
Distribution and characterization of [^3H]mesulergine binding in human brain postmortemMarazziti, D. / Rossi, A. / Giannaccini, G. / Zavaglia, K.M. / Dell'Osso, L. / Lucacchini, A. / Cassano, G.B. et al. | 1999
- 27
-
Rat brain monoamines after acute and chronic myo-inositol treatmentEinat, H. / Belmaker, R.H. / Kopilov, M. / Klein, E. / Gazawi, H. / Ben-Shachar, D. et al. | 1999
- 31
-
Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in miceAlvarez, J.-C. / Sanceaume, M. / Advenier, C. / Spreux-Varoquaux, O. et al. | 1999
- 37
-
Effects of the 5-HT"1"A receptor agonist ipsapirone on operant self-administration of ethanol in the ratSchreiber, R. / Manze, B. / Haussels, A. / De Vry, J. et al. | 1999
- 43
-
Clozapine blocks dopamine, 5-HT"2 and 5-HT"3 responses in the medial prefrontal cortex: an in vivo microiontophoretic studyGobbi, G. / Janiri, L. et al. | 1999
- 51
-
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot studyLoonen, A.J.M. / Doorschot, C.H. / Oostelbos, M.C.J.M. / Sitsen, J.M.A. et al. | 1999
- 59
-
Differential tissue distribution of the enantiomers of racemic pindolol in the ratYan, H. / Lewander, T. et al. | 1999
- 63
-
Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brainBrambilla, A. / Baschirotto, A. / Grippa, N. / Borsini, F. et al. | 1999
- 69
-
Subchronically applied phencyclidine fails to disrupt prepulse inhibition in ratsEhrhardt, J. / Sabel, B.A. / Schroeder, U. et al. | 1999
- 77
-
5-HT3 receptor antagonists and anxiety; a preclinical and clinical reviewOlivier, B. / van Wijngaarden, I. / Soudijn, W. et al. | 2000
- 97
-
Intracellular pH modulates spontaneous and epileptiform bioelectric activity of hippocampal CA3-neuronesBonnet, U. / Bingmann, D. / Wiemann, M. et al. | 2000
- 105
-
Increased adenylyl cyclase type 1 mRNA, but not adenylyl cyclase type 2 in the rat hippocampus following antidepressant treatmentJensen, J. B. / Mikkelsen, J. D. / Mork., A. et al. | 2000
- 107
-
Animal models of anxiety and depression: from behavior to genomicsHen, R. et al. | 2000
- 107
-
The treatment of schizophrenia in the next decadesKane, J. et al. | 2000
- 107
-
Mode of action of atypical antipsychotic drugsSvensson, T. H. et al. | 2000
- 111
-
Pharmacoepidemiology of coprescription of antidepressants and antipsychoticsRittmannsberger, H. et al. | 2000
- 111
-
Coprescription of antipsychotics and antidepressants: Why, when and how?Fleischhacker, W. W. et al. | 2000
- 112
-
The clinical advantage of the comedication of atypical antipsychotics and antidepressantsNaber, D. et al. | 2000
- 112
-
Adverse effects of the comedication of neuroleptics and antidepressantsGrohmann, R. / Engel, R. / Hippius, H. / Ruther, E. et al. | 2000
- 113
-
Treatment of psychiatric symptoms in Parkinson's diseaseHoglinger, G. U. / Oertel, W. H. et al. | 2000
- 113
-
Decreased platelet monoamine oxidase activity in female bulimia nervosaCarrasco, J. L. / Diaz-Marsa, M. / Hollander, E. / Cesar, J. / Saiz-Ruiz, J. et al. | 2000
- 114
-
Psychiatric disorders in Multiple SclerosisKumpfel, T. et al. | 2000
- 115
-
Treatment of psychiatric symptoms in epilepsyKramer, G. / Toygar, A. et al. | 2000
- 116
-
Treatment of psychiatric symptoms in amyotrophic lateral sclerosis (ALS)Pongratz, D. et al. | 2000
- 117
-
Treatment of behavioral and psychiatric disorders in Alzheimer's diseaseWahlund, L. O. et al. | 2000
- 118
-
Nicotine dependence: Concepts from animal experimentsStolerman, I. P. et al. | 2000
- 119
-
Nicotine consumption in mental disorders: a clinical epidemiological perspectiveWittchen, H. U. / Sonntag, H. et al. | 2000
- 119
-
Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neurolepticsMaes, M. / Bocchio Chiavetto, L. / Bignotti, S. / Battisa Tura, G. J. / Pioli, R. / Boin, F. / Kenis, G. / Bosmans, E. / de Jongh, R. / Lin, A. et al. | 2000
- 120
-
Treatment of nicotine dependency with bupropionTonnesen, P. et al. | 2000
- 120
-
Opioid involvement in smoking behaviorTejwani, G. A. et al. | 2000
- 121
-
The mode of action of neuropeptides and its relevance for brain diseasesHokfelt, T. / Xu, Z. Q. / Sergeyev, V. / Diez, M. / Broberger, C. / Holmberg, K. / Ubink, R. / Schott, P. / Ogren, S. O. / Kahl, U. et al. | 2000
- 122
-
NK-1 antagonists as antidepressants - clinical studiesKramer, M. et al. | 2000
- 123
-
Opioids and social disturbancesVan Ree, J. M. et al. | 2000
- 124
-
Neuropeptides in animal models of anxietyLandgraf, R. et al. | 2000
- 124
-
CCK and panic disorderBradwejn, J. / Koszycki, D. et al. | 2000
- 125
-
Body dysmorphic disorder: assessment and treatment with serotonergic drugsHollander, E. / Twersky, R. et al. | 2000
- 125
-
MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramineSilver, H. / Youdim, M. B. et al. | 2000
- 126
-
The importance of the serotonergic system in fibromyalgia syndromeSchwarz, M. J. / Bondy, B. / Spaeth, M. / Offenbaecher, M. / Ackenheil, M. et al. | 2000
- 127
-
SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trialPallanti, S. / Quercioli, L. et al. | 2000
- 128
-
New data on serotonergic medication in migrainevan den Brink, A. M. et al. | 2000
- 129
-
Effect of single intracerebroventricular injection of a-interferon on monoamine concentrations in the rat brainKamata, M. / Higuchi, H. / Yoshimoto, M. / Yoshida, K. / Shimizu, T. et al. | 2000
- 129
-
The criteria for evaluating response to antipsychotics in schizophreniaKane, J. et al. | 2000
- 130
-
The use of novel antipsychotics to improve response in schizophrenia: a naturalistic study in poor respondersAltamura, A. C. / Mundo, E. / Bassetti, R. / Sassella, F. / Salvadori, D. / Pioli, M. R. / Caprioli, C. / Bignotti, S. / Tura, G. B. et al. | 2000
- 131
-
Use of typical and atypical antipsychotics in schizophrenia: pharmacological and clinical aspectsMuller, N. / Riedel, M. / Schaub, A. / Bondy, B. / Moller, H. J. / Ackenheil, M. et al. | 2000
- 132
-
Recent advances of pharmacogenetics in psychiatryKerwin, R. et al. | 2000
- 132
-
The effects of olanzapine on neuroendocrine responses induced by the serotonin agonist m-chlorophenylpiperazine (m-CPP)Scheepers, F. E. / Gispen de Wied, C. C. / Kahn, R. S. et al. | 2000
- 133
-
Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIsFrey, R. / Schreinzer, D. / Stimpfl, T. / Vycudilik, W. / Berzlanovich, A. / Kasper, S. et al. | 2000
- 134
-
How to measure addictive behaviour in animal experimentsSpanagel, R. et al. | 2000
- 135
-
Brain circuits involved in cravingNutt, D. J. / Daglish, M. / Weinstein, A. / Lingford-Hughes, A. et al. | 2000
- 136
-
Ultra-rapid detoxification of opioid addictsScherbaum, N. / Heringhaus, A. / Kienbaum, P. / Nebe, J. / Heppekausen, K. / Gastpar, M. et al. | 2000
- 136
-
Methadone maintenance: the recommended doseStrain, E. C. et al. | 2000
- 137
-
Experience with buprenorphineFischer, G. / Eder, H. / Peternell, A. / Topitz, A. / Kraigher, D. et al. | 2000
- 138
-
Antidopaminergic effects of acute tyrosine depletion in healthy subjects and patients with maniaMcTavish, S. F. / McPherson, M. H. / Harmer, C. J. / Clark, L. / Sharp, T. / Goodwin, G. M. / Cowen, P. J. et al. | 2000
- 139
-
New anxiety disorder treatments based on novel neurobiologyGorman, J. M. et al. | 2000
- 140
-
Treatment for Alzheimer's disease - where are we going?Wilcock, G. K. et al. | 2000
- 141
-
The biochemistry and genetics of signal transduction in bipolar disorderBondy, B. / Zill, P. / Baghai, T. / Neumeier, K. et al. | 2000
- 142
-
No differences in inositol monophosphatase activity and GSK-3b immunoreactivity between bipolar patients and normal controls in postmortem brainAgam, G. / Shaltiel, G. / Kozlovsky, N. et al. | 2000
- 143
-
cAMP signalling system in the pharmacotherapy and pathophysiology of bipolar disorderPerez, J. / Tardito, D. / Racagni, G. / Smeraldi, E. / Mori, S. / Zanardi, R. et al. | 2000
- 144
-
The diagnosis and treatment of rapidly cycling bipolar disorderMaj, M. et al. | 2000
- 144
-
New potential targets in the treatment of bipolar disorder: Animal models and neuropeptidesMathe, A. A. / Jimenez Vasques, P. A. / Gruber, S. H. / Angelucci, F. / Husum, H. et al. | 2000
- 145
-
Suppression of serum gonadal steroids in rats by chronic treatment with dopamine and serotonin reuptake inhibitorsRehavi, M. / Attali, G. / Gil-Ad, I. / Weizman, A. et al. | 2000
- 145
-
Acute pharmacotherapy of depression in old age: A systematic analysis focussing on numbers needed to treatKatona, C. / Livingston, G. et al. | 2000
- 146
-
The pharmacological management of psychotic behaviour in the elderlyMcKeith, I. G. et al. | 2000
- 147
-
The use of typical and atypical antipsychotics in the treatment of elderly psychotic patientsDavidson, M. et al. | 2000
- 147
-
Parkinsonism and tardive dyskinesia in elderly patientsGerlach, J. et al. | 2000
- 148
-
The psychopharmacological management of the early phase of Alzheimer's disorderMuller-Spahn, F. et al. | 2000
- 148
-
Animal models of autismGerrits, M. A. / Van den Berg, C. L. / Daenen, E. W. / Wolterink, G. / Van Ree, J. M. et al. | 2000
- 149
-
Molecular Genetics of autism: evidence for susceptibility lociBailey, A. / Maestrini, E. / Paul, A. / Monaco, A. et al. | 2000
- 150
-
Serotonin and autismPoustka, F. et al. | 2000
- 151
-
Atypical neuroleptics and autismVan Engeland, H. et al. | 2000
- 151
-
Brain lithium measurements with 7Li magnetic resonance spectroscopy (MRS): a literature reviewSoares, J. C. / Boada, F. / Keshavan, M. S. et al. | 2000
- 152
-
Do animal models of stroke predict clinical utility?Vornov, J. J. et al. | 2000
- 153
-
Endogenous low molecular weight factors support extensive CNS axon growthBenowitz, L. I. / Soni, D. / Irwin, N. et al. | 2000
- 153
-
Functional repair of global and focal ischaemic brain damage by grafts of conditionally immortal neuroepithelial stem cellsGray, J. A. / Sowinski, P. / Modo, M. / Stroemer, P. / Veizovic, T. / Tang, E. / Watson, W. P. / French, S. J. / Chadwick, A. / Mora, A. et al. | 2000
- 154
-
Neuroprotection and regeneration in spinal cord injuryPrivat, A. / Gaviria, M. / Gimenez, M. / Ribotta, Y. et al. | 2000
- 155
-
The impact of bipolar disordersBourgeois, M. L. et al. | 2000
- 156
-
Comedication in bipolar disorders: a pharmacological viewAckenheil, M. / Montane-Jaime, K. et al. | 2000
- 157
-
The genetics of bipolar disorders: therapeutic implicationsMendlewicz, J. / Souery, D. et al. | 2000
- 157
-
Treatment-algorithms of bipolar disorderKasper, S. / Zohar, J. et al. | 2000
- 158
-
The value of comedication in bipolar disordersWalden, J. / Grunze, H. et al. | 2000
- 159
-
The use of knockout mice to study the role of 5-HT receptors in animal models of depressionHen, R. et al. | 2000
- 159
-
Role of 5-HT1B receptors in the activity of antidepressants in animal modelsBourin, M. / Gardier, A. et al. | 2000
- 159
-
Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in miceSimon, V. M. / Parra, A. / Minarro, J. / Arenas, M. C. / Vinader-Caerols, C. / Aguilar, M. A. et al. | 2000
- 160
-
The presynaptic function as target for antidepressantsPopoli, M. / Consogno, E. / Nocera, A. / Racagni, G. et al. | 2000
- 161
-
Clinical consequences of the control of NA and 5-HT release in antidepressant therapyBlier, P. et al. | 2000
- 161
-
Patterns of response to serotonergic antidepressantsBenkert, O. / Szegedi, A. / Muller, M. J. et al. | 2000
- 162
-
Psychosocial stress as a trigger for the adaptive modification of neuronal circuitryHuther, G. et al. | 2000
- 163
-
Long term consequences in animals of a stress experiencePiazza, P. V. / Deroche, V. / Rouge-Pont, F. / Marinelli, M. / Barrot, M. / Le Moal, M. et al. | 2000
- 163
-
Maladaptation to stress in schizophreniaGispen-de Wied, C. C. et al. | 2000
- 164
-
Stress and depression: from vulnerability to treatmentNewport, D. J. / Nemeroff, C. B. et al. | 2000
- 165
-
The Munich vulnerability study on affective disorders: HPA system changes as risk factorsModell, S. et al. | 2000
- 165
-
Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trialDannon, P. N. / Sasson, Y. / Hirschmann, S. / Iancu, I. / Grunhaus, L. J. / Zohar, J. et al. | 2000
- 166
-
Targeted mutation of benzodiazepine receptors: new insights into structure and functionMohler, H. et al. | 2000
- 167
-
Partial agonist benzodiazepines: Clinical experiencesKavoussi, R. et al. | 2000
- 168
-
Neuroimaging benzodiazepine receptors: effects of disease and drugsLingford-Hughes, A. et al. | 2000
- 169
-
Insights into the mechanisms of benzodiazepine dependenceDoble, A. / Martin, I. et al. | 2000
- 170
-
GAD: Current treatment and costsLecrubier, Y. / Weiller, E. et al. | 2000
- 171
-
Older antidepressant drugs for generalized anxiety disorder: developing the conceptRickels, K. / Rynn, M. et al. | 2000
- 171
-
Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisiaPoyurovsky, M. / Nave, R. / Epstein, R. / Tzischinsky, O. / Schneidman, M. / Barnes, T. R. / Weizman, A. / Lavie, P. et al. | 2000
- 172
-
Recent developments in the pharmaco-therapy of generalized anxiety disorderDen Boer, J. A. / Bosker, F. J. / Cremers, T. I. / Westerink, B. H. et al. | 2000
- 173
-
Do the benzodiazepines still have a role in the treatment of GAD?Lader, M. et al. | 2000
- 174
-
Neuronal nicotinic receptors in neurodegenerative disordersNordberg, A. et al. | 2000
- 174
-
Can we model GAD experimentally in volunteers?Szabadi, E. / Bradshaw, C. M. et al. | 2000
- 175
-
Nicotinic receptors in Alzheimer's diseaseWevers, A. et al. | 2000
- 176
-
Nicotinic receptors and neurotrophic factorsBelluardo, N. / Mudo, G. / Blum, M. / Fuxe, K. et al. | 2000
- 177
-
Subtype selective nicotine agonistsLloyd, K. et al. | 2000
- 177
-
Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brainBesson, A. / Haddjeri, N. / Blier, P. / de Montigny, C. et al. | 2000
- 178
-
Nicotinic treatment of degenerative neuropsychiatric disordersNewhouse, P. A. / Kelton, M. / Potter, A. / Kahn, H. / Corwin, J. et al. | 2000
- 179
-
fMRI in normal functioning and psychiatric disordersGabrieli, J. D. et al. | 2000
- 180
-
Cognition, antipsychotic drugs, and treatment responseMeltzer, H. et al. | 2000
- 180
-
Glucocorticoids & cognition in depressionSchatzberg, A. F. / DeBattista, C. / Posener, J. et al. | 2000
- 180
-
Beyond phrenology: using functional MRI to study brain dynamicsBerns, G. S. et al. | 2000
- 181
-
Receptors and ligandsPertwee, R. G. et al. | 2000
- 182
-
CB1 receptor mediated effects on brain neurotransmitter systemsVan Vliet, B. J. / Nievelstein, H. N. / Long, S. K. / Kruse, C. G. et al. | 2000
- 183
-
Behavioral effects of cannabinoid agonistsLichtman, A. H. / Martin, B. R. et al. | 2000
- 184
-
Synthetic cannabinoids, potential therapeutic agents of the central nervous systemPop, E. et al. | 2000
- 185
-
The epidemiology, natural history, and pharmacoeconomics, of social anxiety and PTSDKessler, R. C. et al. | 2000
- 186
-
Diagnostic dilemmas in social anxiety disorder and posttraumatic stressStein, D. J. et al. | 2000
- 187
-
Comprehensive treatment of social anxiety disorderBaldwin, D. et al. | 2000
- 189
-
Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acidRichardson, A. J. / Easton, T. / Puri, B. K. et al. | 2000
- 189
-
Neurobiology of anxiety disorders: Focus on neuroimagingWestenberg, H. G. et al. | 2000
- 190
-
Treating PTSD - SSRI's and beyondZohar, J. / Sasson, Y. / Amital, D. et al. | 2000
- 191
-
Neuronal nicotinic subtype selective agonists in treatment of dementiaKem, W. R. et al. | 2000
- 191
-
New avenues in the treatment of dementiaWinblad, B. / Nordberg, A. et al. | 2000
- 192
-
Cholinesterase inhibitors in the treatment of dementiaAnand, R. et al. | 2000
- 193
-
The role of atypical antipsychotics in managing dementiaDe Deyn, P. P. et al. | 2000
- 194
-
The use of oestrogen in the prevention and treatment of Alzheimer's diseaseMaki, P. M. et al. | 2000
- 195
-
Functional MRI: current use and future prospects in human and animal researchMorris, P. G. et al. | 2000
- 195
-
Long-term efficacy and safety of donepezil in the treatment of Alzheimer`s disease: final analysis of a US multicentre open-label studyRogers, S. L. / Doody, R. S. / Pratt, R. D. / Ieni, J. R. et al. | 2000
- 196
-
Behavioural challenges and functional brain imaging in anxiety disordersMalizia, A. L. et al. | 2000
- 197
-
Functional neuroanatomy of schizophreniaMcGuire, P. K. et al. | 2000
- 197
-
Neuroreceptor imaging in depressionGrasby, P. / Sargent, P. / Rabiner, E. / Messa, C. / Bench, C. / Cowen, P. et al. | 2000
- 198
-
SPECT imaging of drug effects in humansSchlaepfer, T. E. et al. | 2000
- 199
-
Molecular pharmacology of the histamine H3 receptorSchwartz, J. C. / Morisset, S. / Rouleau, A. / Gbahou, F. / Ligneau, X. / Tardivel-Lacombe, J. / Heron, A. / Arrang, J. M. et al. | 2000
- 199
-
Modulation of neurotransmitter release via histamine H3 receptorsSchlicker, E. / Kathmann, M. et al. | 2000
- 200
-
The histamine H3 receptor and its relation to normal and altered behaviorMonti, J. M. et al. | 2000
- 201
-
What are the optimal tests for determining enhanced cognitive function in humans?Wesnes, K. A. et al. | 2000
- 202
-
Cognitive and sleep effects of antihistamines: Human studiesAlford, C. / Hindmarch, I. / Stanley, N. / Yorke, L. et al. | 2000
- 203
-
Mood spectrum and residual symptomsCassano, G. B. et al. | 2000
- 203
-
New data on augmentation strategies in depressionArtigas, F. et al. | 2000
- 204
-
The use of thyroid hormones as augmentation strategy in depressionBauer, M. / Berghoefer, A. / Bschor, T. / Baumgartner, A. et al. | 2000
- 205
-
Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathwaysFrisch, A. / Michaelovsky, E. / Rockah, R. / Amir, I. / Hermesh, H. / Laor, N. / Fuchs, C. / Zohar, J. / Lerer, B. / Buniak, S. F. et al. | 2000
- 205
-
Management of resistant depressionSouery, D. et al. | 2000
- 206
-
Serotonin, suicide and impulsivenessAsberg, M. / Forslund, K. et al. | 2000
- 207
-
Dimensions vs categories in OCD-related disordersMarazziti, D. et al. | 2000
- 207
-
Nosologia and treatment of impulse disturbancesSa, H. et al. | 2000
- 208
-
Clinical, biological and treatment characteristics of intermittent explosive disorderCoccaro, E. F. et al. | 2000
- 209
-
NMDA receptor hypofunction and animal models of schizophreniaJentsch, J. D. / Grace, A. A. / Roth, R. H. et al. | 2000
- 210
-
Glutamate receptors in control of dopaminergic systemsSvensson, T. H. et al. | 2000
- 211
-
NMDA-sensitive glutamate antagonism: A human model for psychosisLahti, A. C. / Holcomb, H. H. / Gao, X. M. / Tamminga, C. A. et al. | 2000
- 211
-
Opipramol for the treatment of somatoform disorders results from a placebo-controlled trialVolz, H. P. / Moller, H. J. / Reimann, I. / Stoll, K. D. et al. | 2000
- 211
-
PCP-site ligands and the glutamate hypothesis of schizophreniaKornhuber, J. / Bleich, S. / Wiltfang, J. et al. | 2000
- 212
-
Molecular modeling of the GABAB receptor subdomains: Two putative binding sites in allosteric interaction?Bernard, P. / Guedin, D. / Hibert, M. et al. | 2000
- 212
-
Efficacy and safety of glycine site agonists of the N-methyl-D-aspartate receptor in schizophrenia treatmentHeresco-Levy, U. et al. | 2000
- 213
-
Allosteric properties of G protein-coupled receptors - The example of muscarinic acetylcholine receptorsBirdsall, N. J. / Lazareno, S. et al. | 2000
- 214
-
5-HT-moduline, an endogenous allosteric modulator of 5-HT1B receptorFillion, G. / Massot, O. / Grimaldi, B. et al. | 2000
- 214
-
Allosteric modulation of adenosine receptorsIjzerman, A. P. / Van der Klein, P. A. / De Ligt, R. A. / Kourounakis, A. P. et al. | 2000
- 217
-
Excess TPH 17 779C allele in surviving cotwins of monozygotic twin suicide victimsRoy, A. / Rylander, G. / Forslund, K. / Asberg, M. / Mazzanti, C. / Goldman, D. / Nielsen, D. et al. | 2000
- 217
-
Discriminative stimulus properties of the selective serotonin uptake inhibitor, citalopram, in rats: Generalization with duloxetine, venlafaxine and clomipramine, but blockade by mirtazapine and mianserinDekeyne, A. / Iob, L. / Millan, M. J. et al. | 2000
- 217
-
The differential reinforcement of low-rate (DRL) 72 model for characterization of antidepressant agents: Noradrenaline, but not serotonin or dopamine, uptake inhibitors mimic the actions of imipramineDekeyne, A. / Adhumeau-Auclair, A. / Girardon, S. / Millan, M. J. et al. | 2000
- 218
-
Using cluster analysis to identify subtypes within a study population following treatment with a new pentapeptide antidepressant (statistical and clinical aspects)Feighner, J. P. / Sverdlov, L. / Noble, J. F. / Nicolau, G. / Ehrensing, R. / Kastin, A. et al. | 2000
- 219
-
Bipolar II chronic depression: effects of age at onset on clinical featuresBenazzi, F. et al. | 2000
- 219
-
Prevalence of depressive mixed states in depressed outpatientsBenazzi, F. et al. | 2000
- 219
-
Inhibition of phenprocoumon anticoagulation by carbamazepineSchlienger, R. / Kurmann, M. / Drewe, J. / Muller-Spahn, F. / Seifritz, E. et al. | 2000
- 220
-
Fluoxetine in panic disorder: a randomized, placebo-controlled studyMichelson, D. / Allgulander, C. / Bjorling, G. / Dantendorfer, K. / Dejanovic, S. / Knezevic, A. / Maierhofer, D. / Micev, V. / Paunovic, V. R. / Skoglund, L. et al. | 2000
- 220
-
Evaluation of incidence, prevalence and time-course of depression after acute myocardial infarctionSathananthan, K. / Canepa-Anson, R. / Hamlet, S. et al. | 2000
- 220
-
Occurrence of mirtazapine-induced delirium in organic brain disorder - Three case reportsBailer, U. / Fischer, P. / Kufferle, B. / Stastny, J. / Kasper, S. et al. | 2000
- 221
-
Gender differences in the antidepressive effect? A double blind trial of fluoxetine and maprotiline in the treatment of major depressionMartenyi, F. / Dossenbach, M. / Mraz, K. / Metcalfe, S. et al. | 2000
- 221
-
Sexual functional during acute and continuation therapy with fluoxetine: a prospective assessmentMichelson, D. / Schmidt, M. E. et al. | 2000
- 221
-
Intracerebroventricular antisense to inositol monophosphatase 1 reduces the enzyme activity but does not affect Li-sensitive behaviorShaltiel, G. / Shamir, A. / Belmaker, R. H. / Agam, G. et al. | 2000
- 222
-
Tardive dyskinesia exacerbating with mania: a case reportEsel, E. / Turan, M. T. / Basturk, M. / Kartalc, S. / Oguz, A. / Gonul, A. S. et al. | 2000
- 222
-
The relevance of serum carbamazepine levels in affective and schizoaffective disordersDegner, D. / Schink, C. / Bleich, S. / Kornhuber, J. / Ruther, E. et al. | 2000
- 223
-
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmissionJoca, S. R. / Skalisz, L. L. / Beijamini, V. / Vital, M. A. / Andreatini, R. et al. | 2000
- 223
-
Comparison of the effects of the monoamines oxidase inhibitor tranylcypromine and its 4-fluoro analogue in the forced swimming test in miceBourin, M. / Hascoet, M. / Colombel, M. C. / Coutts, R. T. / Baker, G. B. et al. | 2000
- 223
-
Effects of the 5-HT2C agonist, RO 60-0175, on the antidepressant drug action in the mouse forced swimming testBourin, M. / Clenet, F. et al. | 2000
- 223
-
Physical signs in psychiatry - a step towards evidence based medicineGupta, R. K. / Kasper, S. et al. | 2000
- 224
-
Imidazoline receptors: potential markers for depression and targets of antidepressant drug developmentHalaris, A. / Piletz, J. et al. | 2000
- 224
-
The modulatory effects of hypericum (St. John's wort) and its chemical constituent hyperforin in passive avoidance in the rat: comparative studies with paroxetine and imipramineMisane, I. / Ogren, S. O. et al. | 2000
- 225
-
Sertraline versus imipramine in non-melancholic depressionBaca, E. / Gonzalez de Chavez, M. / Garcia-Toro, M. / Perez-Arnau, F. / Rivera, A. / Penasa, B. / Oliveros, S. / Espejo, J. / Porras-Chavarino, A. / Lane, R. et al. | 2000
- 225
-
Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatientsSchatzberg, A. F. / Cantillon, M. et al. | 2000
- 226
-
Efficacy of reboxetine in patients with severe major depressionMontgomery, S. / Stahl, S. / Ferguson, J. / Mendels, J. / Schwartz, G. et al. | 2000
- 226
-
Effects of reboxetine on HAM-D factors among depressed patientsFerguson, J. / Mendels, J. / Montgomery, S. / Stahl, S. / Schwartz, G. et al. | 2000
- 226
-
Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trialSteiner, M. / Trzepacz, P. T. / Brown, E. et al. | 2000
- 227
-
Predictors of death in bipolar disorderTsai, S. Y. / Kuo, C. J. / Lee, H. C. / Chen, C. C. / Su, K. P. et al. | 2000
- 227
-
Effects of psychotropic agents on plasma levels of soluble interleukin-2 and interleukin-6 receptors in bipolar maniaLee, H. C. / Tsai, S. Y. / Leu, S. J. / Yang, Y. Y. / Chen, K. P. et al. | 2000
- 227
-
The relative effectiveness of selective serotonin reuptake inhibitors and tricyclic antidepressants in reducing worker absenteeismNeslusan, C. A. / Treglia, M. et al. | 2000
- 228
-
Depression, disability and service use in primary health care in six countriesHerrman, H. / Diehr, P. / Fleck, M. / Simon, G. / Patrick, D. et al. | 2000
- 228
-
Mirtazapine versus amitriptyline in treatment of major depressive disorderTuran, M. / Askin, R. / Telcioglu, M. / Cilli, A. S. et al. | 2000
- 229
-
The treatment of depression in the psychiatric practice in Switzerland: a survey studyDelini-Stula, A. / Deutschmann, R. / Schneider, M. / Holsboer-Trachsler, E. et al. | 2000
- 229
-
Effortful and effortless deficits of cognitive processing in clinical depressionPolitis, A. / Oulis, P. / Hatzimanolis, I. / Rigas, G. / Christodoulou, G. N. / Stefanis, C. N. et al. | 2000
- 229
-
Subchronic fluoxetine administration to rats: effects on 5-HT autoreceptor activity as measured by in vivo microdialysisDremencov, E. / Gur, E. / Lerer, B. / Newman, M. E. et al. | 2000
- 230
-
Differential efficacy of venlafaxine ER and fluoxetine in patients with major depressive disorder and co-morbid generalized anxiety disorderSilverstone, P. H. / Hackett, D. / Salinas, E. O. et al. | 2000
- 230
-
Social adjustment of patients with depression is improved with effective treatment: a venlafaxine study in general practiceLecrubier, Y. / Mahe, V. / Hackett, D. / Haudiquet, V. et al. | 2000
- 231
-
Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depressionHawley, C. J. / Sivakumaran, T. / Ochocki, M. / Bevan, J. et al. | 2000
- 231
-
Repetitive transcranial magnetic stimulation in major depression - The impact of stimulation intensity on therapeutic efficacyZwanzger, P. / Thoma, H. / Mikhaiel, P. / Ella, R. / Hampel, H. / Moller, H. J. / Padberg, F. et al. | 2000
- 232
-
Association of angiotensin I converting enzyme gene I/D polymorphism with therapeutic outcome in depressive disorderBaghai, T. C. / Minov, C. / Schule, C. / Zwanzger, P. / Schwarz, M. J. / De Jonge, S. / Rupprecht, R. / Bondy, B. et al. | 2000
- 232
-
Hypothalamic-pituitary-adrenal (HPA) axis activity and response to transcranial magnetic stimulation in responders and nonresponders to sleep deprivationSchule, C. / Padberg, F. / Baghai, T. / Zwanzger, P. / Minov, C. / Moller, H. J. / Rupprecht, R. et al. | 2000
- 233
-
Angiotensin-converting-enzyme gene I/D polymorphism is associated with hyperactivity of the HPA system in depressive patientsMinov, C. / Baghai, T. C. / Schule, C. / Zwanzger, P. / Schwarz, M. J. / De Jonge, S. / Bondy, B. / Rupprecht, R. et al. | 2000
- 233
-
Depression in general practice: Symptoms recognised and treatedRasmussen, J. G. / Kosky, N. J. et al. | 2000
- 234
-
Baseline characteristics of major depressive disorder patients in clinical trials: Is there a transatlantic difference?Niklson, I. A. / Reimitz, P. E. et al. | 2000
- 234
-
Coordinate manifestation in corticotropin-releasing hormone (CRH) and monoaminergic systems after chronic variable stress in the rat brainNagashima, H. / Misonoh, A. / Fujii, S. / Hasegawa, H. / Sasuga, Y. / Osada, K. / Asakura, M. et al. | 2000
- 235
-
Cardiovascular risk factors and lithium in bipolar disorderKlumpers, U. M. / Tulen, J. H. / Loonen, A. J. / Boom, K. / Janssen, F. M. / Pepplinkhuizen, L. et al. | 2000
- 235
-
Autonomic neurocardiac regulation in major depressive disorderVolkers, A. C. / Tulen, J. H. / Van den Broek, W. W. / Bruijn, J. A. / Passchier, J. / Pepplinkhuizen, L. et al. | 2000
- 236
-
Weight gain associated with valproate vs. lamotrigine monotherapy in patients with epilepsy: A randomized, double-blind comparative clinical trialBiton, V. / Mirza, W. / Montouris, G. / Earl, N. / Vuong, A. / Hammer, A. / Barrett, P. et al. | 2000
- 236
-
A one-year open-label study of the safety and efficacy of lamotrigine in the treatment of bipolar depressionBentley, B. / Ascher, J. / Earl, N. / Monaghan, E. / Evoniuk, G. / Batey, S. / Dempsey, G. / El-Mallakh, R. / DeBus, J. / Cohen, A. et al. | 2000
- 236
-
Anxiolysis associated with antidepressant response to bupropion sustained release or sertralineRush, A. J. / Trivedi, M. H. / Batey, S. R. / Donahue, R. M. / Carmody, T. J. / Houser, T. L. / Ascher, J. A. / Bolden-Watson, C. / Evoniuk, G. / Metz, A. et al. | 2000
- 237
-
A one-year continuation study of lamotrigine treatment in bipolar depressionHuffman, R. / Ascher, J. / Earl, N. / Monaghan, E. / Womble, G. / Mitchell, P. / Cookson, J. / Vanier, B. / Dinan, T. / Calabrese, J. et al. | 2000
- 237
-
Mood stabilisation with lamotrigine in rapid cycling bipolar disorderEarl, N. / Greene, P. / Ascher, J. / Fouche, N. / Chang, C. / Evoniuk, G. / Swann, A. / Pope, S. / Ketter, T. / McElroy, S. et al. | 2000
- 237
-
N6-2-(4-Aminophenyl)ethyl-adenosine enhances the anticonvulsive action of conventional antiepileptic drugs in the kindling model of epilepsy in ratsBorowicz, K. K. / Kleinrok, Z. l. / Czuczwar, S. l. et al. | 2000
- 238
-
Mood stabilisation with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled studyKusumakar, V. / Greene, P. / Earl, N. / Ascher, J. / Monaghan, E. / Smoot, T. / Fouche, N. / Bowden, C. / Calabrese, J. / Post, R. et al. | 2000
- 238
-
Assessing the validity of a model of cost-effectiveness of fluvoxamine in depression in France using observational data on treatment patternsPiercy, J. / Nuijten, M. J. et al. | 2000
- 238
-
CYP2D6 phenotype and genotype analysis in polymedicated depressed inpatientsHaffen, E. / Paintaud, G. / Vandel, P. / Broly, F. / Vandel, S. / Nezelof, S. / Bonin, B. / Kantelip, J. P. / Bizouard, P. / Bechtel, P. R. et al. | 2000
- 239
-
Risperidone as an adjunctive treatment in mixed maniaVieta, E. / Corbella, B. / Benabarre, A. / Reinares, M. / Martinez, G. / Fernandez, A. et al. | 2000
- 239
-
Economic aspects of nefazodone, CBASP, and their combination for the treatment of chronic depressionRussell, J. M. / Crown, W. H. / Arnow, B. A. / Blalock, J. A. / Dunner, D. L. / Hirschfeld, R. M. / Kocsis, J. H. / Koran, L. M. / Kornstein, S. G. / Manber, R. et al. | 2000
- 240
-
Bipolar disorder: A cyclical condition requiring a multiphasic approach to managementKusumakar, V. et al. | 2000
- 240
-
Risperidone therapy in bipolar disorder: Results from a 6-month open-label study in SpainVieta, E. / Benabarre, A. / Martinez, G. / Fernandez, A. / Gasto, C. et al. | 2000
- 240
-
Efficacy and tolerability of risperidone versus placebo in combination with lithium or valproate in acute maniaSachs, G. / Ghaemi, S. N. et al. | 2000
- 241
-
Efficacy of venlafaxine in depressed patients after switching from prior SSRI treatmentReynaert, C. / Janne, P. / Zdanowicz, N. / Mignon, A. et al. | 2000
- 241
-
Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatmentDe Clercq, M. / Mignon, A. et al. | 2000
- 242
-
Predictors of hypomania occurring during the antidepressant treatmentZivanovic, O. / Borisev, L. / Borisev, V. / Paunovic, V. R. et al. | 2000
- 242
-
Symptom relief obtained with Venlafaxine versus fluoxetine in depressed patients with concomitant anxietyDe Nayer, A. / De Clercq, M. / Mignon, A. et al. | 2000
- 242
-
A naturalistic study of reboxetine in the Spanish psychiatric practiceBobes, J. / De la Gandara, J. / Such, P. et al. | 2000
- 243
-
Sleep EEG measures in major depression: Predictive markers for long-term courseHatzinger, M. / Hemmeter, U. / Baumann, K. / Annen, B. / Holsboer-Trachsler, E. et al. | 2000
- 243
-
Short term and long term effects of venlafaxine and trimipramine on cognitive psychomotor performance in patients with major depressionHemmeter, U. / Bruderlin, U. / Hatzinger, M. / Annen, B. / Holsboer-Trachsler, E. et al. | 2000
- 244
-
Benefits and risks of antidepressants in hospital useReyntens, J. / De Boever, W. / Wirix, H. / De Bruycker, A. / Bilo, R. / Van Ganse, E. et al. | 2000
- 244
-
Reboxetine does not influence parasympathetic mediated autonomic neurocardiac regulation (ANR)Agelink, M. W. / Lemmer, W. et al. | 2000
- 245
-
Reboxetine vs desipramine and imipramine: An overview of tolerabilityVersiani, M. et al. | 2000
- 245
-
Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT2A and a1-adrenoceptor antagonismMarcus, M. M. / Nomikos, G. G. / Svensson, T. H. et al. | 2000
- 245
-
Reboxetine, a novel selective NRI, in the treatment of panic disorderVersiani, M. et al. | 2000
- 246
-
Risperidone treatment for acute mania: assessment of tolerabilityBowden, C. / Sachs, G. et al. | 2000
- 246
-
Depression during mania: treatment response to olanzapine or placeboBaker, R. W. / Tohen, M. / Risser, R. C. / Stauffer, V. L. / Breier, A. / Tollefson, G. D. et al. | 2000
- 246
-
Topiramate shows efficacy against mania in an open study with an on-off-on protocolGrunze, H. / Normann, C. / Schaefer, M. / Schloesser, S. / Marcuse, A. / Walden, J. et al. | 2000
- 247
-
Effects of tryptophan depletion and repetitive transcranial magnetic stimulation on human sleepHajak, G. / Cohrs, S. / Wortelboer, U. / Lange, K. / Rodenbeck, A. et al. | 2000
- 247
-
Olanzapine in the treatment of juvenile bipolar disorderFrazier, J. A. / Tohen, M. / Biederman, J. / Jacobs, T. / Toma, V. / Feldman, P. et al. | 2000
- 247
-
Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorderNamjoshi, M. / Rajamannar, G. / Risser, R. / Tohen, M. / Breier, A. et al. | 2000
- 248
-
Doxepin in the treatment of primary insomnia - A placebo-controlled, double-blind, polysomnographic studyHajak, G. / Rodenbeck, A. / Voderholzer, U. / Riemann, D. / Cohrs, S. / Hohagen, F. / Berger, M. / Ruther, E. et al. | 2000
- 248
-
The influence of antidepressive treatment on EEG in depressive patientsJernajczyk, W. / Wierzbicka, A. / Antczak, J. / Czasak, K. / Trojecka, A. et al. | 2000
- 249
-
Outcome predictors in bipolar disorder: a catamnestic studyAmore, M. / Casagrande, C. / Melucci, V. / Torroni, A. / Croci, R. / Beverini, E. / Ferrari, G. et al. | 2000
- 249
-
Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depressionJanuel, D. / Poirier, M. F. / D'Alche-Biree, F. / Dib, M. / Olie, J. P. et al. | 2000
- 249
-
The SSRI/5-HT2A antagonist YM992 produces inverse effects compared to SSRIs on the firing activity of noradrenergic neuronsSzabo, S. T. / Blier, P. et al. | 2000
- 250
-
The effects of citalopram metabolites on dog heart in vitro: an electrophysiological studyFaivre, J. F. / Forest, C. F. / Tulloch, I. / Bril, A. et al. | 2000
- 250
-
Efficacy and tolerability of risperidone as combination therapy in bipolar mania: results from a randomised, double-blind study (RIS-INT-46)Yatham, L. N. et al. | 2000
- 251
-
Effectiveness of tramadol as antidepressant in the learned-helplessness model of depressionMico, J. A. / Rojas-Corrales, M. O. / Moreno-Brea, M. R. / Ortega-Alvaro, A. / Roca-Vinardell, A. / Gilbert-Rahola, J. et al. | 2000
- 251
-
Regulation of 5-HT1A and 5-HT4 receptors in rat hippocampus by antidepressants and corticosteroneBijak, M. / Zahorodna, A. / Tokarski, K. et al. | 2000
- 252
-
Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled studySvestka, J. / Synek, O. et al. | 2000
- 252
-
Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depressionDebonnel, G. / Gobbi, G. / Turcotte, J. / Boucher, N. / Hebert, C. / De Montigny, C. / Blier, P. et al. | 2000
- 253
-
Evidence for an association between a G-protein-b3-gene variant with depression and response to antidepressant treatmentZill, P. / Baghai, T. / Zwanzger, P. / Schule, C. / Minov, C. / Rupprecht, R. / Riedel, M. / Neumeier, K. / Bondy, B. et al. | 2000
- 253
-
Effect of amitriptyline treatment on the mRNA levels of the transcription factors c-jun, c-fos and zif 268 on immortalized lymphocytes of depressed patientsZill, P. / Baghai, T. / De Jonge, S. / Neumeier, K. / Bondy, B. et al. | 2000
- 253
-
Penetration of antidepressant drug into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1ab P-glycoprotein disruptionUhr, M. / Boll, E. / Steckler, T. / Yassouridis, A. / Holsboer, F. et al. | 2000
- 254
-
Differential effects of tricyclic antidepressants and paroxetine on gait performance in depressionLemke, M. R. / Wendorff, T. et al. | 2000
- 254
-
The incidence and duration of missed doses during SSRI treatmentMeijer, W. / Bouvy, M. / Heerdink, E. R. / Urquhart, J. / Leufkens, H. G. et al. | 2000
- 255
-
Cardiologic relations of citalopram drop infusion therapyKovacs, G. / Kelemen, E. / Kiraly, L. et al. | 2000
- 255
-
Effects of nefazodone on the immune system of miceFreire-Garabal, M. / Varela, M. / Riveiro, P. / Balboa, J. / Linares, D. / Mana, P. / Mayan, J. M. / Rey-Mendez, M. / Nunez, M. J. et al. | 2000
- 255
-
The effect of antidepressant drugs on transcriptional activity of dopamine D2 receptor gene promoter in the NB41A3 cells - In vitro studyGoralska, M. / Kucharska, A. / Sobota, R. / Dziedzicka-Wasylewska, M. et al. | 2000
- 255
-
The synergistic effect of amantadine and antidepressant drugs in the forced swimming test in ratsMaj, J. / Rogoz, Z. et al. | 2000
- 256
-
Correlation between alpha2-adrenoreceptors and symptom severity in major depressionMarazziti, D. / Baroni, S. / Masala, I. / Di Nasso, E. / Giannaccini, G. / Cassano, G. B. et al. | 2000
- 256
-
Cortisol promotes non-REM sleep in patients with major depressionSchmid, D. A. / Brunner, H. / Holsboer, F. / Friess, E. et al. | 2000
- 256
-
Five-year maintenance treatment with citalopram in recurrent major depressive disorderVavrusova, L. / Konikova, M. / Benedekova, Z. et al. | 2000
- 257
-
Serum cholesterol level and suicidal thoughtsKecskes, I. / Rihmer, Z. / Belso, N. / Pestality, P. / Kiss, K. et al. | 2000
- 257
-
Pharmacological profile of newly synthesized oxotechnitium ligands for the in vivo imaging of brain 5-HT1A receptorsDrossopoulou, G. / Dalla, C. / Antoniou, K. / Papagianopoulou, D. / Pirmettis, I. / Maina, T. H. / Papadopoulos, M. / Chiotellis, E. / Papadopoulou-Daifotis, Z. et al. | 2000
- 257
-
Effects of reboxetine and paroxetine compared to placebo on cognitive processes in healthy volunteersStraube, E. R. / Steil, R. / Kriese, B. / Kimmel, M. / Sauer, H. / Schuler, P. / Volz, H. P. et al. | 2000
- 258
-
Electroconvulsive therapy in treatment resistant bipolar disorder - Case reportsSoares, M. B. / Moreno, R. A. / Moreno, D. H. et al. | 2000
- 258
-
Gender differences in the response to sertraline versus imipramine in non-melancholic depressionBaca, E. / Porras-Chavarino, A. et al. | 2000
- 259
-
Association study of affective disorders with genetic polymorphisms of monoamine oxidasesMuller-Siecheneder, F. / Rujescu, D. / Szegedi, A. / Anghelescu, I. / Giegling, I. / Gietl, A. / Schafer, M. / Moller, H. J. / Dahmen, N. et al. | 2000
- 259
-
Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candidate on chromosome 21q22.3Rujescu, D. / Szegedi, A. / Anghelescu, I. / Giegling, I. / Gietl, A. / Schafer, M. / Muller-Siecheneder, F. / Bondy, B. / Moller, H. J. / Dahmen, N. et al. | 2000
- 260
-
Antidepressant associated suicidalityHealy, D. et al. | 2000
- 260
-
Memory assessment 25 years after ECT treatmentKohl, C. / Gwiggner, M. / Gurka, P. / Bodner, T. / Kemmler, G. / Hinterhuber, H. / Marksteiner, J. et al. | 2000
- 260
-
Sertraline and fluoxetine treatment of OCD: a 6-month, double-blind, parallel studyBergeron, R. / Hadrava, V. / Ravindran, R. et al. | 2000
- 261
-
Better than well on antidepressantsHealy, H. / Cattell, D. / Tranter, R. / Jaffar, K. / Healy, D. et al. | 2000
- 261
-
Simultaneous use of sertraline and hormonal replacement therapy (HRT) in women with major depression during the menopausal periodKrogulski, S. / Lipinska-Sza&lz.xl / ek, A. / Rabe-Jab&lz.xl / onska, J. et al. | 2000
- 261
-
Effects of pharmacotherapy to depression in the period of adolescenceMunjiza, M. / Ljubomirovic, N. / Vidojevic, P. et al. | 2000
- 262
-
Depression in the psychiatric practice in Switzerland: a survey studyHolsboer-Trachsler, E. / Deutschmann, R. / Delini-Stula, A. et al. | 2000
- 262
-
Theobromine and tryptophan alone or in association lack potential antidepressant-like effects whereas chronic paroxetine is effective in a genetic mouse model of depressive disorderEl Yacoubi, M. / Costentin, J. / Vaugeois, J. M. et al. | 2000
- 263
-
Onset of action of mirtazapine on depression related symptoms: factor analysis of pooled data mirtazapine versus SSRIsSchutte, A. J. / Van Hensbeek, I. / Reimitz, P. et al. | 2000
- 263
-
Sexual dysfunctions in depressed outpatients during long-term therapy with moclobemide and SSRIs - The results of an open, prospective, observational studyFauchere, P. A. / Antonioli, D. / Mullor, R. / Bischoff, S. / Delini-Stula, A. et al. | 2000
- 264
-
Donepezil in therapy-refractory depressionKemmerich, M. / Quartz, P. / Berger, F. M. / Kuthmann, A. et al. | 2000
- 264
-
Onset of action of mirtazapine on anxiety symptoms related to depressionVan Hensbeek, I. / Schutte, A. J. / Reimitz, P. et al. | 2000
- 264
-
Fluoxetine and amitriptyline: differential cognitive effects in depressed patientsIvkovic, M. / Jasovic-Gasic, M. / Maric, N. / Paunovic, V. R. et al. | 2000
- 265
-
Unaltered a2-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysisGross-Isseroff, R. / Weizman, A. / Fieldust, S. J. / Israeli, M. / Biegon, A. et al. | 2000
- 265
-
Mirtazapine and the onset of antidepressant action: survival function analysis-responseNierenberg, A. A. / Kremer, C. / Reimitz, P. et al. | 2000
- 265
-
Mirtazapine has similar long-term efficacy and tolerability to citalopram and faster onset of action in the treatment of major depressionLeinonen, E. / Skarstein, J. / Behnke, K. / Angren, H. / Schutte, A. J. et al. | 2000
- 265
-
Mirtazapine in relapse prevention: a double-blind placebo-controlled study in depressed outpatientsThase, M. E. / Nierenberg, A. A. / Keller, M. B. et al. | 2000
- 266
-
Comparison of antidepressant-like activity of Lu 28-179, a selective 2 ligand, citalopram and imipramine in a chronic mild stress model of depression in ratsPapp, M. / Sanchez, C. et al. | 2000
- 266
-
Efficacy and tolerability of mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholiaGuelfi, J. D. / Van Hensbeek, I. / Ansseau, M. / Korsgaard, S. / Timmerman, L. et al. | 2000
- 266
-
Mirtazapine and onset of action of antidepressant activityMontgomery, S. / Schutte, A. J. / Reimitz, P. et al. | 2000
- 267
-
Choice of method and lethality in suicidal behaviour - overdoses during a 14 years period in Baranya region, HungaryFekete, S. / Osvath, P. / Jegessy, A. et al. | 2000
- 267
-
Morning and evening plasma melatonin and dexamethasone suppression test in non-seasonal major depressive patients from Northern Greece (latitude 40-41.5degree)Fountoulakis, K. N. / Karamouzis, M. / Iacovides, A. / Nimatoudis, J. / Diakogiannis, J. / Kaprinis, G. / Demitriadou, A. / Bech, P. et al. | 2000
- 268
-
Sleep disturbance in affective disorders: relationship to family historyPapadimitriou, G. N. / Dikeos, D. G. / Daskalopoulou, E. G. / Soldatos, C. R. et al. | 2000
- 268
-
Chronobiological lithium effects in rats with lesion of suprachiasmatic nucleusZamoshchina, T. / Meleshko, M. et al. | 2000
- 269
-
The new prolonged lithium compoundsZamoshchina, T. / Isupov, V. / Matveyenko, A. et al. | 2000
- 269
-
Antidepressant or immunomodulator induced regulation of cell signalling in brain and immune systemKovaru, H. / Fiserova, A. / Kovaru, F. / Paclt, I. / Lisa, V. et al. | 2000
- 270
-
Verbal memory deficits associated with unipolar affective disorderTotic, S. / Marinkovic, D. / Maric, N. / Brankovic, S. / Jasovic-Gasic, M. / Paunovic, V. R. et al. | 2000
- 270
-
Interaction of tricyclic antidepressants with liposomesFisar, Z. et al. | 2000
- 271
-
Significance of the brain mineralocorticoid receptor in stress and stress-related mental disordersGesing, A. / Bilang-Bleuel, A. / Droste, S. / Linthorst, A. C. / Reul, J. M. et al. | 2000
- 271
-
Acute and chronic treatment with the selective glucocorticoid receptor antagonists ORG 34850, ORG 34116 and ORG 34517 alters multiple parameters of the rat hypothalamic-pituitary-adrenocortical systemBachmann, C. G. / Linthorst, A. C. / Reul, J. M. et al. | 2000
- 272
-
Effects of dexamethasone on various immunological parameters in patients with major depressionSchuld, A. / Kraus, T. / Hinze-Selch, D. / Haack, M. / Zobel, A. W. / Pollmacher, T. et al. | 2000
- 272
-
Weight gain during treatment with mirtazapine goes along with an increase in plasma levels of cytokines and leptinKraus, T. / Haack, M. / Schuld, A. / Pollmacher, T. et al. | 2000
- 272
-
The anxiolytic effect of the novel CRH1 receptor antagonist R121919 depends on innate emotionality in ratsKeck, M. E. / Welt, T. / Renner, U. / Wigger, A. / Landgraf, R. / Holsboer, F. et al. | 2000
- 273
-
The "discontinuation syndrome" in depressed patients successfully treated with sertralineDan, I. A. / Simu, M. et al. | 2000
- 273
-
The GABA-B antagonist CGP 36742 prevent PTZ-kindling-provoked amnesia in ratsGenkova-Papazova, M. G. / Petkova, B. / Shishkova, N. / Lazarova-Bakarova, M. et al. | 2000
- 273
-
Cognitive components of somatosensory evoked potentials in major depressive disorderDietl, T. / Dirlich, G. / Vogl, L. / Lechner, C. / Nickel, T. / Sonntag, A. / Strian, F. et al. | 2000
- 274
-
Suicidal behavior in patients with recurrent brief depression (RBD)Pezawas, L. / Stamenkovic, M. / Jagsch, R. / Ackerl, S. / Putz, C. / Stelzer, B. / Aschauer, H. / Kasper, S. et al. | 2000
- 274
-
No evidence of lateralized effects on mood after slow repetitive transcranial magnetic stimulation (rTMS) in healthy volunteersHermelink, D. / Juckel, G. / Zwanzger, P. / Hampel, H. / Moller, H. J. / Padberg, F. et al. | 2000
- 275
-
Auditory evoked potentials as indicator of serotonergic neuronal activity - An animal study using microinjection techniques into the dorsal raphe nucleusJuckel, G. / Hegerl, U. / Molnar, M. / Csepe, V. / Karmos, G. et al. | 2000
- 275
-
CRH, HPA system hyperactivity and depressionZobel, A. W. / Nickel, T. / Kunzel, H. / Ackl, N. / Sonntag, A. / Ising, M. / Holsboer, F. et al. | 2000
- 275
-
Cortisol response to the Dex/CRH test predicts medium-term-outcome in patients with remitted depressionZobel, A. W. / Frieboes, R. M. / Ising, M. / Holsboer, F. et al. | 2000
- 276
-
Modulation of sleep EEG and nocturnal hormone secretion by neuropeptide Y in patients with depression and normal controlsSteiger, A. / Held, K. / Strohbusch, S. / Antonijevic, I. A. / Murck, H. / Frieboes, R. M. et al. | 2000
- 276
-
The selective noradrenalin reuptake inhibitor induces similar sleep EEG changes like SSRI's in patients with depressionKuenzel, H. E. / Murck, H. / Ziegenbein, M. / Held, K. / Steiger, A. et al. | 2000
- 277
-
Sleep-endocrine alterations in women with depression are markedly enhanced after menopauseAntonijevic, I. A. / Murck, H. / Frieboes, R. M. / Steiger, A. et al. | 2000
- 277
-
Fast adaptive changes of the sleep regulatory system after the putative antidepressant EMD 68 843Murck, H. / Frieboes, R. M. / Antonijevic, I. A. / Steiger, A. et al. | 2000
- 278
-
Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms and the pro-/anti-inflammatory cytokine balanceKelly, J. P. / Connor, T. J. / Nolan, Y. / Shen, Y. / Leonard, B. E. et al. | 2000
- 278
-
Citalopram versus amitriptyline in elderly patients with or without dementia. A Danish multicentre trial in general practiceRosenberg, C. / Hopfner Petersen, H. E. et al. | 2000
- 278
-
Onset of response to fluoxetine treatment as assessed by the symptom questionnaireSonawalla, S. / Hutchins, A. / Delgado, M. / Johnson, M. / Worthington, J. / Alpert, J. / Fava, M. et al. | 2000
- 279
-
MRI signal hyperintensities and chronicity of depressionHeiden, A. / Kettenbach, K. / Fischer, P. / Schein, B. / BaSsalamah, A. / Frey, R. / Gulesserian, T. / Itzlinger, U. / Trattnig, S. / Imhof, H. et al. | 2000
- 279
-
Oral administration of losartan influences aminopeptidase activity in the frontal cortexPrieto, I. / Martinez, J. M. / Hermoso, F. / Ramirez, M. J. / Vargas, F. / De Gasparo, M. / Alba, F. / Ramirez, M. et al. | 2000
- 279
-
Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and b1-adrenergic receptors in an animal model of depressionKelly, J. P. / Harkin, A. / Nally, R. / Leonard, B. E. et al. | 2000
- 280
-
1H-MR-Spectroscopy of untreated depressive patients shows reduced N-acetyl aspartate, choline and myo-inositol levels in the frontal lobeFrey, R. / Gruber, S. / Ortwein-Swoboda, G. / Heiden, A. / Mlynarik, V. / Moser, E. / Kasper, S. et al. | 2000
- 280
-
Dose-dependent antidepressive effect of new analogues of excitatory amino acids in forced swimming testParshev, V. V. / Onishchenko, N. V. / Sergeyev, V. S. / Piotrovsky, L. B. / Petrov, V. I. et al. | 2000
- 280
-
Reboxetine plus citalopram in treatment resistant depressionDevarajan, S. / Dursun, S. M. et al. | 2000
- 281
-
The effect of clonidine in the treatment of acute maniaTudorache, B. et al. | 2000
- 281
-
Use of risperidone in psychotic and non-psychotic patients with bipolar disorderPetty, F. / Sachs, G. / Bowden, C. et al. | 2000
- 281
-
Subjective evaluation of psychopharmacology and its outcome in schizophreniaJarema, M. / Murawiec, S. / Szafranski, T. / Koniczynska, Z. / Szaniawska, A. et al. | 2000
- 282
-
Low levels of antibodies to cardiolipin in first episode and chronic schizophreniaSirota, P. / Bodanov, I. / Katzav, A. / Hershko, R. / Chapman, J. et al. | 2000
- 282
-
A naturalistic study of changing attitudes of antipsychotic prescribing patterns in an inpatient service from TurkeySoykan, A. / Ozsan, H. / Celik, S. et al. | 2000
- 283
-
An open study of buspirone augmentation of neuroleptics in schizophrenic patientsSirota, P. / Epstein, B. / Benatov, R. / Sousnostzky, M. / Kindler, S. et al. | 2000
- 283
-
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patientsGonul, A. S. / Basturk, M. / Sofuoglu, S. / Kula, M. / Esel, E. / Turan, T. / Yabanoglu, I. et al. | 2000
- 283
-
Altered brain protein kinase C in depression: a post-mortem studyCoull, M. A. / Lowther, S. / Katona, C. L. / Horton, R. W. et al. | 2000
- 283
-
Marked improvement in tardive dyskinesia with olanzapine treatment: a case reportEsel, E. / Sofuoglu, S. / Turan, M. T. / Gonul, A. S. et al. | 2000
- 284
-
Risperidone is effective in patients with treatment-resistant schizophreniaKocmur, M. / Tavcar, R. / Dernovsek, M. Z. et al. | 2000
- 284
-
A more favorable clinical outcome with sulpiride augmentation in a patient with chronic schizophrenia partially responsive to OlanzapineWitz, S. / Kosov, I. / Assael-Amini, M. / Abramovich, Y. et al. | 2000
- 285
-
Contrasting effects of typical and atypical antipsychotics on neuronal viability and functioning of the anterior cingulate region in chronic schizophrenia: A MRSI studyBraus, D. F. / Ende, G. / Weber-Fahr, W. / Henn, F. A. et al. | 2000
- 285
-
Clozapine treatment of different psychosesGaszner, P. et al. | 2000
- 286
-
Perception of chimeric faces and the brain's pattern of asymmetry in schizophreniaKucharska-Pietura, K. / Loza, B. / Klimkowski, M. et al. | 2000
- 286
-
Perception of emotional prosody among schizophrenic patientsKucharska-Pietura, K. / Loza, B. et al. | 2000
- 286
-
Behavioural asymmetry as a predictor of acute treatment efficacy in paranoid schizophreniaLoza, B. / Kucharska-Pietura, K. et al. | 2000
- 287
-
Implications of dichotic listening effects for dimensional structure of paranoid schizophreniaLoza, B. / Kucharska-Pietura, K. et al. | 2000
- 287
-
Age-related factor structure of schizophrenic symptomatologyLoza, B. / Kucharska-Pietura, K. et al. | 2000
- 288
-
Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychoticsHarvey, P. D. / Meltzer, H. Y. / Romano, S. et al. | 2000
- 288
-
Improvement in indices of health status following a switch to ziprasidone from conventional and novel antipsychoticsDaniel, D. G. / Weiden, P. J. / O'Sullivan, R. L. et al. | 2000
- 288
-
Ziprasidone's effect on anxiety in a group of outpatients with stable schizophreniaSchooler, N. R. / Siu, C. et al. | 2000
- 289
-
Pharmacokinetics of ziprasidone in children and adolescents with Tourette's syndromeSallee, F. R. / Miceli, J. J. / Wilner, K. D. / Robarge, L. et al. | 2000
- 289
-
An overview of the efficacy and safety of rapid-acting intramuscular ziprasidoneDaniel, D. G. / Brook, S. / Reeves, K. R. et al. | 2000
- 289
-
Benefits of ziprasidone in stable outpatient schizophrenics switched from conventional antipsychotics, olanzapine, or risperidoneSimpson, G. M. / Potkin, S. G. / Weiden, P. J. / O'Sullivan, R. L. et al. | 2000
- 289
-
Obesity as a risk factor for antipsychotic noncomplianceWeiden, P. J. / Mackell, J. / McDonnell, D. D. et al. | 2000
- 289
-
Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humansLiechti, M. E. / Vollenweider, F. X. et al. | 2000
- 290
-
M100907 in schizophrenic and schizoaffective patientsKablinger, A. S. / Freeman, A. M. et al. | 2000
- 290
-
Healthcare resource use and body mass index among individuals with schizophreniaAllison, D. B. / Mackell, J. et al. | 2000
- 290
-
The effect of risperidone on psychotic symptom and information processing in first episode schizophreniaHyun, S. B. / Kim, J. G. / Hong, K. S. / Kim, E. et al. | 2000
- 291
-
Effects of new antipsychotics on serum prolactin and testosterone in schizophrenic patientsHan, D. H. / Park, D. B. / Na, C. et al. | 2000
- 291
-
Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophreniaRobinson, G. / Wheeler, A. / Byrd, J. / Visser, S. et al. | 2000
- 291
-
Brain activation in schizophrenic patients and healthy controls during working memory and mental arithmetic. a functional magnetic resonance imaging (fMRI) studyLund, A. / Thomssen, T. / Stordal, K. / Kroken, R. / Smievoll, A. I. / Barndon, R. / Ersland, L. / Lundervold, A. / Mjellem, N. / Egeland, J. et al. | 2000
- 292
-
Risperidone effect on positive and negative symptoms of schizophrenia: A nine-month follow-up study of 375 patientsCervera-Enguix, S. / Giner, J. / Ortuno, F. / Pla, J. / Soutullo, C. / Fernandez, A. et al. | 2000
- 292
-
A comparison of the effects on cognitive function of E-5842 administered as a single or multiple doseTaubel, J. / Arezina, R. / Ward, T. / Wesnes, K. A. et al. | 2000
- 292
-
Comparison of the costs and effects of treatment with risperidone versus olanzapine in daily practiceLoos, J. C. / Van Zonneveld, T. H. / Loone, A. J. et al. | 2000
- 293
-
DU 127090: a highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potentialVan Vliet, B. J. / Mos, J. / Van der Heijden, J. A. / Feenstra, R. / Kruse, C. G. / Long, S. K. et al. | 2000
- 293
-
Comparison of indications and treatment outcomes of risperidone in elderly and younger patientsVan Zonneveld, T. H. / Loos, J. C. / Loonen, A. J. et al. | 2000
- 294
-
DU 127090: a highly potent, atypical dopamine receptor ligand - high potency but low efficacy at dopamine D2 receptors in vitroVan Vliet, B. J. / Ronken, E. / Tulp, M. / Feenstra, R. / Kruse, C. G. / Long, S. K. et al. | 2000
- 294
-
DU 127090: a highly potent, atypical dopamine receptor ligand - pilot study of dopamine D2 receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using 11C-raclopride by means of positron emission tomographyDe Vries, M. H. / Udo de Haes, J. / Long, S. K. / Grahnen, A. / Nyman, L. / Bergstrom, M. / Wall, A. / Langstrom, B. et al. | 2000
- 295
-
Impact of early intervention with intramuscular antipsychotic medication in an acute care settingMartinez, J. M. / Russell, J. M. / Salinas, H. / Mackell, J. A. et al. | 2000
- 295
-
DU 127090: a highly potent, atypical dopamine receptor ligand - partial agonist character in neurochemistry assays in vivoLong, S. K. / Feenstra, R. / Kruse, C. G. / Van Vliet, B. J. et al. | 2000
- 295
-
Relationship between inadequate physical healthcare and poor mental health among individuals with schizophreniaRussell, J. M. / Mackell, J. A. et al. | 2000
- 296
-
Risperidone olanzapine drug outcomes study in schizophrenia (RODOS) pooled results from German centersAlbus, M. et al. | 2000
- 296
-
Risperidone oral solution versus intramuscular haloperidol for control of psychotic agitationCurrier, G. W. / Simpson, G. A. et al. | 2000
- 296
-
Cognitive symptoms in schizophrenic patients treated with risperidone compared to other neurolepticsKlauder, A. / Rettig, K. et al. | 2000
- 297
-
An international survey on information needs of patients with schizophrenia and their carers and management issues most frequently encountered by professional care team membersWaerner, T. / Bassi, M. / Dubuis, J. / Fleischhacker, W. W. / Kissling, W. / Linszen, D. / Remington, G. / Turner, T. / Wallace, M. et al. | 2000
- 297
-
A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of maniaKeck Jr, P. E. / Ice, K. et al. | 2000
- 297
-
ECNP Consensus Meeting, March 5-6, 1999, Nice| 2000
- 298
-
Drug attitude inventory, spanish-adapted versionGarcia Cabeza, I. / Hormaechea Beldarrain, J. A. / Sanz Amador, M. / Arango Lopez, C. / Gonzalez de Chavez, M. et al. | 2000
- 298
-
Incomplete forms of the neuroleptic malignant syndrome: A continuation of a case seriesZicanovic, O. / Borisev, L. / Borisev, V. et al. | 2000
- 298
-
Reduced central muscarinic acetylcholine receptor availability in vivo in schizophrenic patientsRaedler, T. J. / Knable, M. B. / Jones, D. W. / Urbina, R. A. / Gorey, J. G. / Lee, K. S. / Egan, M. / Weinberger, D. R. et al. | 2000
- 299
-
Compliance with neuroleptics in schizophrenic patients prior to inpatient treatmentRittmannsberger, H. / Pachinger, T. / Keppelmuller, P. et al. | 2000
- 299
-
Drug daily dosage in schizophrenia inpatients receiving conventional versus atypical neuroleptic agentsRitsner, M. / Ponizovsky, A. / Nechamkin, Y. / Dahan, M. / Caspi, N. / Birman, E. / Modai, I. et al. | 2000
- 300
-
Retrospective 1-year review of the outcomes of atypical antipsychotic use at Central Texas Veterans Health Care SystemClark, W. / Defilippi, J. et al. | 2000
- 300
-
The effect of quetiapine in improving cognitive impairment in schizophreniaHellewell, J. S. et al. | 2000
- 300
-
Clinical predictors of acute response with quetiapine in psychotic mood disordersZarate, C. A. / Rothschild, A. / Fletcher, K. E. / Madrid, A. / Zapatel, J. et al. | 2000
- 301
-
Use of the number needed to treat to evaluate clinical trials of quetiapine and other atypical antipsychoticsDonoghue, J. et al. | 2000
- 301
-
Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: a multinational survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychoticsHellewell, J. S. / Gorman, A. P. et al. | 2000
- 302
-
Efficacy of quetiapine compared with haloperidol and placebo in the short-term treatment of acute schizophreniaSchulz, S. C. et al. | 2000
- 302
-
Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezilParsa, M. A. / Poggi, E. / Barte, L. et al. | 2000
- 303
-
New findings suggest weak anticholinergic profile of olanzapineTran, P. / Bymaster, F. / Kennedy, J. / Basson, B. / Czekalla, J. / Street, J. / Clark, S. et al. | 2000
- 303
-
Safety during long-term exposure to quetiapineGorman, A. P. / Westhead, E. K. et al. | 2000
- 303
-
Global index of safety (GIS): a new instrument to assess drug safety: application to a prospective pharmacoepidemiological study (EFESO)Sacristan, J. A. / Gomez, J. C. / Badia, X. / Kind, P. / Gavart, S. et al. | 2000
- 304
-
A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patientsWright, P. / Birkett, M. / Ferchland, I. / David, S. / Alaka, K. / Pullen, P. / Brook, S. / Reinstein, M. / Breier, A. et al. | 2000
- 304
-
Relapse prevention with olanzapineBeasley Jr, C. / Hamilton, S. / Dossenbach, M. et al. | 2000
- 305
-
Predictive value of early antianxiety effect on the acute-antipsychotic outcome: a comparison of fluphenazine and olanzapineMartenyi, F. / Dossenbach, M. / Jakovljevic, M. / Metcalfe, S. et al. | 2000
- 305
-
Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adultsPhilipp, M. / Tiller, J. W. / Baier, D. / Kohnen, R. et al. | 2000
- 305
-
Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapineKinon, B. J. / Basson, B. / Hill, A. L. / Berg, P. H. et al. | 2000
- 305
-
Effect of long-term olanzapine treatment on weight change in schizophreniaGilmore, J. / Kinon, B. J. / Basson, B. R. / Tollefson, G. D. et al. | 2000
- 306
-
Effects of risperidone and typical antipsychotics on basal ganglia volumes in patients with schizophreniaHoner, W. G. / Lang, D. J. / Vandorpe, R. A. / Rui, Q. / Smith, G. N. / Milliken, H. M. / Goghari, V. M. / Kopala, L. C. et al. | 2000
- 306
-
Pharmacokinetics, tolerability, and safety of aripiprazole following single and multiple oral dose administrationMallikaarjun, S. / Salazar, D. E. / Bramer, S. L. et al. | 2000
- 306
-
Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidoneKinon, B. J. / Basson, B. / Wang, J. / Malcolm, S. K. / Stauffer, V. L. et al. | 2000
- 307
-
Tolerability, efficacy and cognitive effects of quetiapine in patients with Parkinson's disease treated for psychotic symptomsJuncos, J. L. / Evatt, M. L. / Jewart, R. D. / Roberts, V. J. / Wood, C. D. / Potter, L. S. / Jou, H. C. / Yeung, P. P. et al. | 2000
- 307
-
Clozapine plasma levels and time to clinical response in a standardized trialLa Pia, S. / Fabrazzo, M. / Bencivenga, R. / Esposito, G. / Pinto, A. / Sannino, A. / Maj, M. et al. | 2000
- 308
-
Switch to risperidone and olanzapine in the cohort of young schizophrenic patientsChojnacka, J. / Taflinski, T. et al. | 2000
- 308
-
Atypical antipsychotics and dopamine D1 receptor agonism: an in vivo experimental study using core temperature measurements in the ratAhlenius, S. / Oerther, S. et al. | 2000
- 309
-
Obsessive-compulsive symptoms in schizophrenic patients treated with clozapineTaflinski, T. et al. | 2000
- 309
-
The effect of atypical vs typical antipsychotic drugs on the results of neurocognitive tests in schizophrenic patientsRybakowski, J. K. / Borkowska, A. et al. | 2000
- 309
-
Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placeboCarson, W. H. / Kane, J. M. / Ali, M. / Dunbar, G. C. / Ingenito, G. et al. | 2000
- 310
-
Risperidone Olanzapine Drug Outcomes Study (RODOS): the first English resultsMartin, S. / Wright, T. et al. | 2000
- 310
-
Deficit/nondeficit schizophrenia: psychopathological evaluations and treatmentLeuci, E. / Marotta, M. T. / Garlini, S. / Uslenghi, S. / Pelizza, L. / Maggini, C. et al. | 2000
- 311
-
QTc prolongation associated with sulpiride and haloperidol use: A pilot crossover-design studySu, K. P. / Chen, K. P. / Shen, W. W. / Tsai, S. Y. et al. | 2000
- 311
-
Optimal risperidone dosage in drug-naive first-episode schizophrenic patientsKontaxakis, V. P. / Havaki-Kontaxaki, B. J. / Stamouli, S. S. / Christodoulou, G. N. et al. | 2000
- 312
-
Olanzapine-induced neuroleptic malignant syndromeKontaxakis, V. P. / Havaki-Kontaxaki, B. J. / Christodoulou, N. G. / Paplos, K. G. / Christodoulou, G. N. et al. | 2000
- 312
-
Neuroleptic malignant syndrome induced by risperidone and clozapine combinationKontaxakis, V. P. / Havaki-Kontaxaki, B. J. / Stamouli, S. S. / Christodoulou, G. N. et al. | 2000
- 313
-
The use of atypical antipsychotics in the university psychiatric hospital in AthensKontaxakis, V. P. / Havaki-Kontaxaki, B. J. / Kollias, C. / Stamouli, S. / Margariti, M. / Christodoulou, G. N. et al. | 2000
- 313
-
Depression measures and motor side-effects among schizophrenic inpatientsKontaxakis, V. P. / Havaki-Kontaxaki, B. J. / Stamouli, S. / Margariti, M. / Kollias, C. / Christodoulou, G. N. et al. | 2000
- 313
-
Olanzapine-associated neuroleptic malignant syndrome: Is there any overlap with the serotonin syndrome?Kontaxakis, V. P. / Havaki-Kontaxaki, B. J. / Christodoulou, N. G. / Paplos, K. G. / Christodoulou, G. N. et al. | 2000
- 314
-
Neurological signs in schizophrenia patients: The influence of atypical versus classical antipsychotic drugsBoks, M. P. / Russo, S. / Knegtering, R. / Den Boer, J. A. / Van den Bosch, R. J. et al. | 2000
- 314
-
Antipsychotic-induced parkinsonism in newly treated outpatientsSchillevoort, I. / Herings, R. M. / Roos, R. A. / Jansen, P. A. / Leufkens, H. G. et al. | 2000
- 315
-
The effects of antipsychotic drugs on serotonergic activity in the rat hippocampusAntoniou, K. / Bekris, S. / Saranti, M. / Stathis, P. / Rimikis, M. / Papadopoulou-Daifoti, Z. et al. | 2000
- 315
-
Low-dose amisulpride: some evidence for alertness-increasing properties in EEG studiesLegangneux, E. / Rosenzweig, P. / Saletu, B. / Allain, H. et al. | 2000
- 315
-
Dimensions of psychopathology in schizophrenia: a factor analysis of the amisulpride databaseRein, W. et al. | 2000
- 316
-
A one year cost-effectiveness model for the treatment of chronic schizophrenia in BelgiumDe Hert, M. / Van Dijk, M. / Lecomte, P. / Nuyts, G. et al. | 2000
- 316
-
Inpatient treatment of schizophrenia: a real-life study of two leading atypical antipsychoticsKasper, S. / Duchesne, I. et al. | 2000
- 317
-
Long-term treatment with clozapine: a study with plasma levelsMauri, M. C. / Laini, V. / Scalvini, M. / Cerveri, G. / Ferrari, V. / Volonteri, L. S. / Giuliani, E. / Papa, P. et al. | 2000
- 317
-
A meta-analysis of efficacy and safety of risperidone and olanzapinePeuskens, J. / De Hert, M. / Jones, M. et al. | 2000
- 318
-
A genetic polymorphism coding for 129Val in the prion protein is associated with decreased cortical gray matter volume in schizophrenic patients but not in controlsRujescu, D. / Kirner, A. / Giegling, I. / Leinsinger, G. / Hegerl, U. / Moller, H. J. / Meisenzahl, E. M. et al. | 2000
- 318
-
PPI deficits in antipsychotic-treated, chronic schizophrenic patientsLudewig, K. / Leumann, L. R. / Etzensberger, M. / Vollenweider, F. X. et al. | 2000
- 319
-
Resolution of rapid weight gain on olanzapine after substitution with quetiapineNasr, S. J. et al. | 2000
- 319
-
Successful use of high dose quetiapine in a patient with a psychiatric disorder resistant to olanzapineRobertson Jr, J. B. / Treosti, L. / Walker, K. D. et al. | 2000
- 320
-
Modulation of D2R-mediated mitogenic signalling by APDsRogue, P. / Gensburger, C. / Freyermuth, S. / Malviya, A. et al. | 2000
- 320
-
Quetiapine is effective in a high-risk patient without precipitating the akathisia seen with olanzapine and risperidonePurdon, S. et al. | 2000
- 321
-
Clozapine is efficient in long-term treatment of negative syndrome, but no cognitive functioning, in schizophrenia? A three-year follow-up studyMarinkovic, D. / Totic, S. / Jasovic-Gasic, M. / Maric, N. / Paunovic, V. R. et al. | 2000
- 321
-
Olanzapine vs haloperidol: plasma levels and clinical efficacy on cognitive function in 37 schizophrenic patient (22 olz, 15 hal.)De Vanna, M. / Anzallo, C. / Onor, M. L. / Aguglia, E. et al. | 2000
- 321
-
Differential actions of the new antipsychotic agentsMoore, N. A. / Bymaster, F. P. / Tran, P. / Breier, A. / Tollefson, G. D. et al. | 2000
- 322
-
The use of quantitative magnetic resonance imaging and auditory evoked potentials in schizophrenic patientsMeisenzahl, E. M. / Muller, D. / Frodl, T. / Marcuse, A. / Leinsinger, G. / Juckel, G. / Heiss, D. / Unger, J. / Moller, H. J. / Hegerl, U. et al. | 2000
- 322
-
Dopamine and serotonin plasma blood level in adolescents with schizophrenia during perphenazine therapyRajewski, A. / Adamczewska-Goncarzewicz, Z. / Dorszewska, J. / Rajewska, J. et al. | 2000
- 323
-
Evaluation of working memory in functional MR imaging with different memory tasksMeisenzahl, E. M. / Kathmann, N. / Heiss, D. T. / Zetzsche, T. / Hahn, K. / Leinsinger, G. L. / Moller, H. J. et al. | 2000
- 323
-
Cortical surface and regional variability in patients with schizophrenia and healthy controlsMeisenzahl, E. M. / Holder, J. J. / Marcuse, A. / Preuss, U. / Leinsinger, G. / Zilles, K. / Moller, H. J. / Schormann, T. et al. | 2000
- 324
-
Quantitative magnetic resonance imaging of the corpus callosum in schizophreniaFrodl, T. / Holder, J. / Greiner, J. / Marcuse, A. / Leinsinger, G. / Heiss, D. / Hegerl, U. / Moller, H. J. / Meisenzahl, E. M. et al. | 2000
- 324
-
Combined striatal dopamin transporter and dopamin D2-receptor-SPECT in drug-naiv schizophrenic patients: a 99mTc-TRODAT-1-123I-IBZM-SPECT studyMeisenzahl, E. M. / Schmitt, G. J. / Frodl, T. / Tatsch, K. / Moller, H. J. / Dresel, S. et al. | 2000
- 324
-
In vivo striatal dopamine D2 receptor binding in drug-naive patients with schizophrenia compared to healthy controls: an 123I-IBZM-SPECT studyFrodl, T. / Schmitt, G. J. / Dresel, S. / Tatsch, K. / Moller, H. J. / Meisenzahl, E. M. et al. | 2000
- 324
-
Striatal dopamin transporter in drug-naive schizophrenic patients: a 99mTc-TRODAT-1-SPECT studySchmitt, G. J. / Frodl, T. / Tatsch, K. / Dresel, S. / Moller, H. J. / Meisenzahl, E. M. et al. | 2000
- 325
-
Risperidone versus pimozide for the treatment of monosymptomatic hypochondriacal psychosisCetin, M. / Ebrinc, S. et al. | 2000
- 325
-
In vivo effects of olanzapine and risperidone on striatal dopamine D2 receptor binding in schizophrenic patients: an 123I-IBZM SPECT studyMeisenzahl, E. M. / Frodl, T. / Schmitt, G. J. / Dresel, S. / Tatsch, K. / Mager, T. / Moller, H. J. et al. | 2000
- 325
-
Amygdala or ventral hippocampal lesions at two early stages of life differentially affect prepulse inhibition of the acoustic startle response; an animal model of a neurodevelopmental disorder like schizophreniaDaenen, E. W. / Wolterink, G. / Van Der Heyden, J. A. / Kruse, C. G. / Van Ree, J. M. et al. | 2000
- 325
-
Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependenceSoyka, M. / De Vry, J. et al. | 2000
- 326
-
Neuropsychological deficits and negative symptoms in patients with first-episode schizophreniaSchaub, A. / Wolf, B. / Charypar, M. / Moller, H. J. et al. | 2000
- 326
-
Meta-analysis of amisulpride - A selective dopamine receptor antagonist with an "atypical" profileLeucht, S. / Pitschel-Walz, G. / Kissling, W. et al. | 2000
- 327
-
Coping-orientated treatment and atypical neuroleptics in an integrated treatment approach for patients with schizophreniaSchaub, A. / Wolf, B. / Gartenmaier, A. / Kaiser, A. / Muller, N. / Moller, H. J. et al. | 2000
- 327
-
Drug combination treatment in acute and subacute states of schizophrenia and schizoaffective disorderMuller, M. J. / Benkert, O. et al. | 2000
- 328
-
Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazineDossenbach, M. et al. | 2000
- 328
-
Costs-benefits of resource utilization in the Quebec welfare recipients population using two atypical drug productsCastilloux, A. M. / Savoie, M. / LeLorier, J. et al. | 2000
- 329
-
Olanzapine vs. chlorpromazine - 6 weeks treatment of acute schizophreniaDossenbach, M. et al. | 2000
- 329
-
Effects of an atypical neuroleptic EMD 128 130 on sleep EEG and nocturnal hormone secretion in young normal controlsHeld, K. / Frieboes, R. M. / Murck, H. / Kunzel, H. / Ziegenbein, M. / Steiger, A. et al. | 2000
- 330
-
No effect of amisulpride on lithium pharmacokineticsCanal, M. / Chaufour, S. / Zieleniuk, I. / Borgstein, N. G. / Pinquier, J. L. et al. | 2000
- 330
-
Amisulpride: kinetics in patients with renal failureCanal, M. / MacMahon, M. / Kwan, J. / Dubruc, C. et al. | 2000
- 331
-
Amisulpride pharmacokinetics: No difference between young and elderly subjectsCanal, M. / Chaufour, S. / Lavanant, C. / Zieleniuk, I. / Piette, J. F. / Deschamps, C. et al. | 2000
- 331
-
Amisulpride does not inhibit cytochrome P450 isozymesGillet, G. / Dormerque, L. / Canal, M. / Thenot, J. P. et al. | 2000
- 332
-
Risperidone is more useful than bromperidol in the treatment of first-episode schizophrenic patientsSuhiyoshi, A. et al. | 2000
- 332
-
Can quality management improve the treatment of schizophrenic outpatients?Seemann, U. / Kissling, W. / Zacher, A. et al. | 2000
- 333
-
Decreased GSK-3&bz.xl; immunoreactivity in postmortem frotal cortex of schizophrenic patientsKozlovsky, N. / Belmaker, R. H. / Agam, G. et al. | 2000
- 333
-
Haptoglobin phenotypes and genotypes in schizophreniaMaes, M. / Bocchio, L. / Zanardini, R. / Bignotti, S. / Tura, G. B. / Pioli, R. / Delanghe, J. / Altamura, C. A. et al. | 2000
- 333
-
DU 127090: A highly potent, atypical dopamine receptor ligand - Behavioral effects of DU 127090 in Cebus non-human primatesCasey, D. E. / Van Vliet, B. J. / Feenstra, R. / Kruse, C. G. / Long, S. K. et al. | 2000
- 333
-
Prevalence and characteristics of patients with pseudoakathisiaHavaki-Kontaxaki, B. J. / Kontaxakis, V. P. / Christodoulou, G. N. et al. | 2000
- 333
-
Fatal neuroleptic intoxications identified at autopsy in Vienna from 1991 to 1997Schreinzer, D. / Frey, R. / Stimpfl, T. / Vycudilik, W. / Berzlanovich, A. / Kasper, S. et al. | 2000
- 334
-
Mezapam reduces basophil releasability in non-atopic allergic skin diseasesStrakhova, M. / Cheburkin, A. / Raba, G. et al. | 2000
- 334
-
Frontal and temporal enlargement of CSF spaces in agoraphobia: a morphometric CT-scan studyWurthmann, C. / Gregor, J. / Bogerts, B. et al. | 2000
- 334
-
Psychiatric disorders and comorbidity in high-dose and low-dose benzodiazepine usersLekka, N. P. / Paschalis, C. / Ellul, J. / Beratis, S. et al. | 2000
- 335
-
A placebo-controlled study of sertraline in generalized social phobiaVan Ameringen, M. A. / Swinson, R. / Walker, J. R. / Lane, R. M. et al. | 2000
- 335
-
Anxiolytic like activity of cyamemazine in mice models of anxietyBourin, M. / Hascoet, M. / Colombel, M. C. et al. | 2000
- 336
-
24-Week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatmentVan Ameringen, M. A. / Walker, J. R. / Swinson, R. / Lane, R. M. et al. | 2000
- 336
-
Efficacy of venlafaxine ER in social adjustment in patients with generalized anxiety disorderBoyer, P. / Mahe, V. / Hackett, D. / Haudiquet, V. et al. | 2000
- 337
-
Venlafaxine ER treatment of GAD: specific benefit of long-term treatmentMeoni, P. / Hackett, D. / Montgomery, S. A. et al. | 2000
- 337
-
Cholecystokinin-antisense oligodeoxynucleotides: a new strategy in the approach to anxiety?Cohen, H. / Kotler, M. et al. | 2000
- 337
-
Efficacy of short and long-term venlafaxine ER treatment on somatic and psychic symptoms of GADHackett, D. / Meoni, P. / White, C. / Rasmussen, J. et al. | 2000
- 337
-
Lymphocyte peripheral benzodiazepine receptor mRNA decreases in obsessive-compulsive disorderRocca, P. / Beoni, A. M. / Eva, C. / Ferrero, P. / Maina, G. / Bogetto, F. / Ravizza, L. et al. | 2000
- 338
-
Survival analyses of discontinuations as evidence of long-term effectiveness of venlafaxine ER in GAD: comparison of venlafaxine ER with placeboMontgomery, S. A. / Mahe, V. / Haudiquet, V. / Hackett, D. et al. | 2000
- 339
-
Improvement of CCK-4 induced panic by selective GABA-transaminase-inhibition with vigabatrinZwanzger, P. / Baghai, T. / Schule, C. / Minov, C. / Padberg, F. / Schwarz, M. / Moller, H. J. / Rupprecht, R. et al. | 2000
- 339
-
Neuroendocrinological, biochemical and psychophysiological characteristics of chronic posttraumatic stress disorderKlumpers, U. M. / Tulen, J. H. / Timmerman, L. / Fekkes, D. / Boomsma, F. / Pepplinkhuizen, L. / Loonen, A. J. et al. | 2000
- 339
-
Thalamic blood flow is reduced in OCD responders to fluvoxamineHo Pian, K. L. / Westenberg, H. G. / Van Megen, H. G. / Ramsey, N. / Van Rijk, P. P. et al. | 2000
- 339
-
Orphanin FQ, an endogenous modulator of stress-induced anxiety states in animalsMoreau, J. L. / Ouagazzal, A. M. / Jenck, F. et al. | 2000
- 340
-
Effects of tiapride on anxiety tested in the light-dark box in male miceCardenas, J. / Navarro, J. F. / Maldonado, E. / Beltran, D. et al. | 2000
- 340
-
Gammahydroxybutyrate (GHB) exhibits anxiogenic-like effects in the "elevated plus maze test" in male miceNavarro, J. F. / Maldonado, E. / Pedraza, C. / Garcia, F. / Luna, G. et al. | 2000
- 341
-
Acute and subchronic effects of MDMA ("ecstasy") on anxiety in the "elevated plus maze test" in male miceMaldonado, E. / Navarro, J. F. / Romero, C. / Martin, M. / Beltran, D. et al. | 2000
- 341
-
Effects of 3,4-methylenedioxymethamphetamine ("ecstasy") on anxiety in the "social interaction test" in male miceMaldonado, E. / Navarro, J. F. / Cardenas, J. / Davila, G. / Cavas, M. et al. | 2000
- 341
-
Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatmentBackman, J. / Alling, C. / Alsen, M. / Regnell, G. / Traskman-Bendz, L. et al. | 2000
- 342
-
Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorderConley, R. R. / Mahmoud, R. et al. | 2000
- 342
-
Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: Safety comparisonsConley, R. R. / Mahmoud, R. et al. | 2000
- 343
-
Autonomic neurocardiac effects of benzodiazepines: A comparison between midazolam, diazepam and lorazepamAgelink, M. W. / Lemmer, W. / Majewski, T. / Klieser, E. et al. | 2000
- 344
-
Exploratory pilot study with olanzapine in generalized anxiety disorder (GAD) showed anxiolytic treatment with low-dosages of the atypical antipsychoticKlieser, E. / Wurthmann, C. / Czekalla, J. / Landefeld, H. / Lemmer, W. / Schulte, T. et al. | 2000
- 344
-
Effects of selective 5-HT2C receptor antagonist, SB 242084, on anxiety and depressive-like behaviour in miceSukhotina, I. A. / Zvartau, E. E. et al. | 2000
- 344
-
Three randomised, placebo-controlled, double-blind trials of pregabalin treatment of Generalized Anxiety Disorder (GAD)Pande, A. C. / Crockatt, J. G. / Feltner, D. E. / Liu-Dumaw, M. / Werth, J. L. et al. | 2000
- 344
-
A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of responseFeltner, D. E. / Pollack, M. H. / Davidson, J. R. / Stein, M. B. / Futterer, R. / Jefferson, J. W. / Lydiard, R. B. / DuBoff, E. / Robinson, P. / Phelps, M. et al. | 2000
- 345
-
Modulation of the serotonergic system and anxiety sensitivityRomano, P. / Ieva, A. / Piccinini, G. / Rolla, A. S. / Bellodi, L. / Perna, G. et al. | 2000
- 345
-
Frontal lobe dysfunction and prediction to treatment outcome in obsessive-compulsive disorderCavedini, P. / Riboldi, G. / D'Annucci, A. / Cisima, M. / Bellodi, L. et al. | 2000
- 346
-
Improved avoidance learning by oxytocin administration in a high-emotional strain of Sprague-Dawley ratsHillegaart, V. / Uvnas-Moberg, K. / Eklund, M. / Ahlenius, S. et al. | 2000
- 346
-
The role of the balance system in panic disorderPerna, G. / Caldirola, D. / Bussi, R. / Rolla, A. S. / Alpini, D. / Cesarani, A. / Bellodi, L. et al. | 2000
- 346
-
Diurnal variation of cortisol in panic disorderBandelow, B. / Wedekind, D. / Sandvoss, V. / Broocks, A. / Hajak, G. / Pauls, J. / Peter, H. / Ruther, E. et al. | 2000
- 347
-
Predictors of treatment response in Panic disorderMenini, M. / Paulillo, G. / Gariboldi, S. / Avanzini, M. / Amore, M. / Maggini, C. et al. | 2000
- 347
-
Paroxetine is effective in the treatment of generalized anxiety disorder: results from a randomized placebo-controlled flexible dose studyMcCafferty, J. P. / Bellew, K. / Zanelli, R. / Iyengar, M. / Hewett, K. et al. | 2000
- 348
-
Sertraline and posttraumatic stress disorder: Results of 24 weeks of open-label sertraline followed by a 28-week discontinuation studyDavidson, J. / Londborg, P. / Pearlstein, T. / Rothbaum, B. / Brady, K. / Farfel, G. et al. | 2000
- 348
-
Separation of systemic physiologic and specific cerebral drug effects in pharmacologic magnetic resonance imaging (phMRI)Kalisch, R. / Elbel, G. K. / Schieferstein, O. / Czisch, M. / Auer, D. P. et al. | 2000
- 349
-
Risperidone augmentation in refractory obsessive compulsive disorder: An open-label studyPfanner, C. / Marazziti, D. / Dell'Osso, L. / Presta, S. / Gemignani, A. / Milanfranchi, A. / Cassano, G. B. et al. | 2000
- 349
-
The anxiolytic-like effect of nafadotride, a dopamine D3 receptor antagonist, in ratsRogoz, Z. / K&lz.xl / ozinska, A. / Maj, J. et al. | 2000
- 350
-
Sleep EEG changes in OCD: A comparison with normal controlsMatos-Pires, A. / Cavaglia, F. / Pires-Barreira, D. / Lara, E. / Atalaia, A. / Arriaga, F. et al. | 2000
- 350
-
Generalised anxiety disorder: An insight into the burden on the individual and societyWittchen, H. U. et al. | 2000